# Ramesh Radhakrishnan

> Ramesh Radhakrishnan is a seed investor at Artiman Ventures backing Machine Learning. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Artiman Ventures](https://shizune.co/investors/profile/artiman-ventures)
- Location: San Francisco, United States
- Total investments: 4
- Last investment: Jun 2024
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ramesh-radhakrishnan-9620831/

Ramesh Radhakrishnan is a seed investor at Artiman Ventures in San Francisco focused on Machine Learning and Artificial Intelligence. Ramesh Radhakrishnan is the Partner & Managing Director at Artiman Ventures. Additionally, Ramesh Radhakrishnan has had 1 past job as the VP of Engineering at FireEye.Ramesh has been a member of the founding entrepreneurial team in three startups. He has over 20 years of operational and business experience in the high technology industry,including networking, security and wireless companies. Prior to joining Artiman Capital India, Ramesh was the VP of Engineering at FireEye, a network security company that uses virtualization technology to detect and combat the menace of malware, botnets and crimeware. Prior to that, Ramesh led the systems and software development team at Airgo Networks. Airgo pioneered and invented the 802.11n MIMO OFDM wireless LAN standards and was acquired by Qualcomm in 2005. Prior to Airgo, Ramesh was the Director of the Wireless Access Business Unit at Cisco Systems. This business unit was the result of the acquisition of Clarity Wireless, a startup company where Ramesh led the engineering team that pioneered and created the wireless last mile standard which is WiMax today. Prior to Clarity Wireless, Ramesh was a founding member at ZeitNet, acquired by Cabletron in 1996, where he led the engineering team which made high speed LAN products. Before this, Ramesh was an engineering manager at Adaptive Corporation that brought ATM technology to the LAN. Adaptive was acquired by NET in 1994. Ramesh started his career as a software engineer at Hewlett Packard's Network Division in Cupertino.Ramesh holds two patents in the area of networking protocol technologies.Ramesh holds a B.E. from the Indian Institute of Technology (IIT), Chennai, and an M.E. in Systems Engineering from the University of Virginia, Charlottesville.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $953k–$6.5M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Machine Learning | 2 | 50% |
| Artificial Intelligence | 2 | 50% |
| Apps | 1 | 25% |
| Medical | 1 | 25% |
| Computer | 1 | 25% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 3 | 75% |
| Series A | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| QpiAI | QpiAI vertically integrates quantum computing and AI for solutions in manufacturing, industrial, transportation, finance, pharmaceuticals, and materials with diverse software platforms and products and provides impactful advances to generative AI and various industry verticals. | $6.5M | Seed | Jun 21, 2024 |  |
| SmarterBiz Technologies | SmarterBiz is an AI-powered customer experience platform that enables remote management of customer journeys and agent life cycles. SmarterBiz has helped several enterprises, including unicorns build scalable, flexible, and hyper-local customer experience, cost-effectively. | $1.1M | Seed | Aug 20, 2020 |  |
| OncoStem Diagnostics | OncoStem Diagnostics Private Limited is Mauritius incorporation with subsidiaries in India and US. It is founded by Cell Biology veteran with significant experience in US, Singapore and India in cancer biology & cancer drug discovery. Of the many challenges in medicine, none has experienced more hard-fought progress than the treatment andcure of cancer. ‘Recurrence’ of cancer is still the single most feared feature of cancer by the patients and oncologists since it is often the cause of morbidity and mortality associated with the disease. Risk of recurrence can vary from cancer to cancer. Accurate prediction of ‘risk of recurrence’ is one of the most important features required to plan optimum and effective treatment. At present, most cancer patients get surgery plus chemotherapy and radiation therapy to prevent cancer recurrence. These treatments are very generic, have severe side effects which reduce quality of life of patients. Finding targeted drugs (e.g. Gleevec, Herceptin) to prevent recurrence is the need of the hour. OncoStem is focussing on these two main issues viz predicting risk of recurrence and developing new targeted drugs to alleviate pain of cancer patients through improved diagnostics. OncoStem is developing novel diagnostic tests which will predict ‘risk of recurrence’ and prescribe targeted drugs to prevent cancer recurrence. Their first focus is breast cancer. | $6M | Series A | Sep 06, 2017 |  |
| OncoStem Diagnostics | OncoStem Diagnostics Private Limited is Mauritius incorporation with subsidiaries in India and US. It is founded by Cell Biology veteran with significant experience in US, Singapore and India in cancer biology & cancer drug discovery. Of the many challenges in medicine, none has experienced more hard-fought progress than the treatment andcure of cancer. ‘Recurrence’ of cancer is still the single most feared feature of cancer by the patients and oncologists since it is often the cause of morbidity and mortality associated with the disease. Risk of recurrence can vary from cancer to cancer. Accurate prediction of ‘risk of recurrence’ is one of the most important features required to plan optimum and effective treatment. At present, most cancer patients get surgery plus chemotherapy and radiation therapy to prevent cancer recurrence. These treatments are very generic, have severe side effects which reduce quality of life of patients. Finding targeted drugs (e.g. Gleevec, Herceptin) to prevent recurrence is the need of the hour. OncoStem is focussing on these two main issues viz predicting risk of recurrence and developing new targeted drugs to alleviate pain of cancer patients through improved diagnostics. OncoStem is developing novel diagnostic tests which will predict ‘risk of recurrence’ and prescribe targeted drugs to prevent cancer recurrence. Their first focus is breast cancer. | $1M | Seed | Jul 01, 2011 |  |

4 of 4 investments shown.

## Co-investors
- [YourNest Venture Capital](https://shizune.co/investors/profile/yournest-venture-capital) — VC Fund, 2 deals together
- [HEM ANGELS](https://shizune.co/investors/profile/hem-angels) — VC Fund, 1 deal together
- [Sahasra capital](https://shizune.co/investors/profile/sahasra-capital) — VC Fund, 1 deal together
- [Peak XV Partners](https://shizune.co/investors/profile/sequoia-india-2) — VC Fund, 1 deal together
- [SIDBI Venture Capital](https://shizune.co/investors/profile/sidbi-venture-capital) — VC Fund, 1 deal together
- [StartupXseed Ventures](https://shizune.co/investors/profile/startupxseed-ventures) — VC Fund, 1 deal together

## About Artiman Ventures

VC Fund · Palo Alto, United States

Artiman is an early-stage venture fund that seeks to invest in entrepreneurs that have the potential to disrupt multi-billion markets. The firm was established in 2000 and is headquartered in Palo Alto, California, United States.

5 contacts available at Artiman Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Ajit Singh | Partner | https://shizune.co/investors/profile/ajit-singh |
| Amit Shah | Founder & Partner | https://shizune.co/investors/profile/amit-shah-2 |
| Ramesh Radhakrishnan | Partner & Managing Director | https://shizune.co/investors/profile/ramesh-radhakrishnan |
| Brian Wilcove | Partner | https://shizune.co/investors/profile/brian-wilcove |
| Mahmood Panjwani | Entrepreneur in Residence | https://shizune.co/investors/profile/mahmood-panjwani |

## Similar investors

### Similar industry
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Titan Capital](https://shizune.co/investors/profile/titan-capital) — VC Fund
- [Inflection Point Ventures](https://shizune.co/investors/profile/inflection-point-ventures-d275) — VC Fund
- [Blume Ventures](https://shizune.co/investors/profile/blume-ventures) — VC Fund

## Featured in investor lists
- [Machine Learning Angel Investors in India](https://shizune.co/investors/machine-learning-angel-investors-india)

## FAQ

### What does Ramesh Radhakrishnan invest in?

Ramesh Radhakrishnan invests primarily in Machine Learning, Artificial Intelligence and Apps startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Ramesh Radhakrishnan's check size?

Ramesh Radhakrishnan typically joins rounds of $953k–$6.5M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ramesh Radhakrishnan participates in.

### When did Ramesh Radhakrishnan last invest?

The most recent investment recorded for Ramesh Radhakrishnan closed in Jun 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co